StreetInsider.com News Articles

Form 4 Kura Oncology, Inc. For: Aug 21 Filed by: Powl Brian T.

Mon, 24 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260824/26969255.html

Form 4 Kura Oncology, Inc. For: Aug 21 Filed by: Powl Brian T.

Mon, 24 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260824/26969255.html

Form 4 Kura Oncology, Inc. For: Aug 24 Filed by: WILSON TROY EDWARD

Mon, 24 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260824/26969256.html

Form 4 Kura Oncology, Inc. For: Aug 24 Filed by: WILSON TROY EDWARD

Mon, 24 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260824/26969256.html

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results

Mon, 24 Aug 2026 04:13:02 -0400

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst commented, "We reiterate our Market Outperform rating and $24 price target on Kura Oncology based on a discounted EPS and revenue multiple analysis. Recently, Kura announced 2Q26 financial results, provided updates on the KOMZIFTI (ziftomenib, zifto) launch, including capturing the majority of new patient starts in r/r NMP1-mutant AML, and highlighted remaining pipeline milestones for 2026. With the KOMZIFTI launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform expected to enter registrational studies

Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.

Fri, 21 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260821/26961955.html

Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.

Fri, 21 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260821/26961955.html

Form 4 Kura Oncology, Inc. For: Aug 19 Filed by: Bair Teresa Brophy

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961796.html

Form 4 Kura Oncology, Inc. For: Aug 19 Filed by: Bair Teresa Brophy

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961796.html

Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy

Wed, 19 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260819/26950388.html

Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy

Wed, 19 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260819/26950388.html

Form 4 Kura Oncology, Inc. For: Aug 17 Filed by: WILSON TROY EDWARD

Mon, 17 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26938562.html

Form 4 Kura Oncology, Inc. For: Aug 17 Filed by: WILSON TROY EDWARD

Mon, 17 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26938562.html

Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931447.html

Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931447.html

Form 10-Q Kura Oncology, Inc. For: Jun 30

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913104.html

Form 10-Q Kura Oncology, Inc. For: Jun 30

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913104.html

Form 8-K Kura Oncology, Inc. For: Aug 12

Wed, 12 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26912930.html

Form 8-K Kura Oncology, Inc. For: Aug 12

Wed, 12 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26912930.html

Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue

Wed, 12 Aug 2026 16:05:26 -0400

Kura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.77), $0.11 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $20.87 million versus the consensus estimate of $20.16 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

Kura Oncology Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:02:00 -0400

– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –